VACCINEX, INC. (VCNX): Nasdaq/NYSE listing notice — Vaccinex receives Nasdaq delisting notice for failing to meet $2.5M equity minimum

VACCINEX, INC.

Stockholders' equity $2.4M as of March 31, 2023; below Nasdaq's $2.5M minimum.
Company has 45 days (until July 9, 2023) to submit a compliance plan to regain compliance.
If plan accepted, extension to Nov 21, 2023 possible; otherwise delisting may occur.
Company plans to submit plan and pursue capital raising, including recent private placement.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

VACCINEX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

completed fiscal years (the “Alternative Standards”). The Notice noted that the Company’s Form 10-Q for the period ended March 31, 2023 disclosed stockholders’ equity of $2.4 million as of March 31, 2023 and that, as of May 24, 2023, the Company did not meet the Alternative Standards. The Notice has no immediate effect on the Company’s listing on the Nasdaq

View on SEC.gov

Browse all listing & compliance notices →

VACCINEX, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-156073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.